

Basic report update – Capital increase

Analyst:

Dr. Roger Becker, CEFA, Biologist, Phone: +49 69-71 91 838-46; roger.becker@bankm.de

Rights offering to accelerate growth and support expansion

- Capital increase of up to 1.35 Mill. new shares
 - Increase in cash capital, strike price at €15.95 per share
 - Gross proceeds up to ca. €21.53 Mill.
 - Subscription period from Nov 19 - Dec 3, 2009 with a 14:5 ratio
 - Trade of subscription rights excluded
 - New shares are fully entitled to dividend for the business year 2009
- Use of proceeds
 - Extension of the segments
 - „Environmental Services“ (equity allotment ca. €10 Mill.)
 - „Radiopharmacy“ (equity allotment ca. €5 Mill.)
 - Strategic acquisitions and international expansion within the segments „Therapy“ and „Industry“ (equity allotment ca. €5 Mill.)
- Management considers doubling of sales up to €200 Mill. within reach by 2014; guidance for 2010: net result stable at €1.80 per share (based on the increased number of shares)
- The economic potential resulting from the current corporate action prompts us to increase our sales and earnings forecasts for the years 2010ff.

With the *ad hoc* release dated Nov 10, 2009, the Company announced a corporate action in order to raise fresh capital of up to €21.5 Mill. by the offering of 1.35 Mill. new shares. The use of proceeds includes a substantial extension of the segment „Environmental Services“ towards the attractive market of radioactive waste conditioning. Simply because of the current issues regarding the shut down mine shaft „Schachtanlage Asse“ (retrieval and conditioning of radioactive waste), a significant upside potential may unfold. Further, the proceeds will provide for the extension of contract manufacturing capacities within the segment „Radiopharmacy“, for the consistent continuation of the company’s acquisition and consolidation strategy and for geographic expansion.

Based on our adjusted DCF analysis and the re-evaluated peer group, we increase our fair value to €22.90 and affirm our “buy” rating. Further, we advise investors to participate in the current capital increase; at a current share price of €19.33 (Nov 16, 2009), the new shares are being issued at a discount of ca. 17%.

Key Financials (in Mill. €, except EPS/DPS)

Year	Sales	EBITDA	EBIT	EBT	adj. Net	adj. EPS	DPS	EBIT Margin	Net Margin
2008	71.61	18.62	9.47	8.30	4.50	1.43	0.25	13.2%	6.3%
2009e	105.83	19.88	14.18	12.76	6.71	1.79	0.30	13.4%	6.3%
2010e	117.10	25.07	19.27	17.62	9.45	1.80	0.32	17.4%	8.1%
2011e	133.72	25.91	20.01	18.66	10.13	1.93	0.45	15.0%	7.6%
2012e	160.41	36.62	30.62	29.57	17.22	3.27	0.48	19.1%	10.7%

Source: BankM Research

Fair Value: €22.90

Buy

Financial Figures	2009e	2010e	2011e
EV/Sales	1.1	1.0	0.8
EV/EBITDA	5.7	4.5	4.4
EV/EBIT	8.0	5.9	5.6
P/E adj.	10.8	10.8	10.0
Price/Bookvalue	0.3	0.2	0.2
Price/FCF	3.6	10.5	5.2
ROE	9.2	11.7	11.4
Dividend yield	1.6	2.3	2.5
Number shares (million, after CI)			5.260
MarketCap / EV (million €, MC before CI)		75.1 / 107.2	
Free Float			55.50%
WKN			565970
ISIN			DE 0005659700
Bloomberg			E UZ GY Equity
Sector			Medical Technology
Accounting			IFRS
Market segment			Regulated Market
Transparency			Prime Standard
Financial Year			Dec 31
Price Nov 16, 2009 (XETRA-close)			€ 19.33



Eckert & Ziegler AG (blue/black), Performance 1 year vs. DAX Subsector MedTech (red/grey)
 Source: Deutsche Börse AG

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

This document has been prepared due to a service agreement with the respective issuer. BankM – Repräsentanz der biw Bank is the designated sponsor of the company’s stock and, in this function, will regularly hold a trading stock or long or short positions in the company’s stock. Equity investments generally involve high risks. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Investors may lose some or all of the money invested. Investors make their decisions at their own risk.

Use of proceeds and background of the current capital increase

1. Extension of the segment „Environmental Services“

With the purchase of the Braunschweig-based company Nuclitec in January, 2009 – now Eckert & Ziegler Nuclitec GmbH (EZN) – the EZAG group acquired a long-established isotope specialist, ranking among the most established companies in the sector, worldwide (see our basic report from April 1, 2009). It has been producing radioactive components for the medical and measurement engineering field for over 30 years. As a result of the acquisition, EZAG strengthens its segments “Nuclear Medicine & Industry” and “Radiopharmacy” and, in addition, extends the scope of its business activities to “Environmental Services”, being integrated as the fourth operating segment of the group. The new segment will reside within the newly founded subsidiary “Kompetenzzentrum für sichere Entsorgung GmbH (KSE; Competence Center for Safe Waste Disposal)”, a spin-off from EZN.

The operations of the new segment consist in the conditioning of short- and long-lived, weak to mid radioactive waste deriving from clinics, scientific institutes, and from industry. Long-lived radioactive waste is being collected in so-called Konrad containers and conditioned for ultimate disposal in the “Schacht Konrad”, Salzgitter. In 2007, the Federal Administrative Court (Bundesverwaltungsgericht) has approved the shaft for ultimate disposal (start in 2014).

The new business field currently gains additional upside potential regarding the issues associated with the “Schachtanlage Asse” (a shut down mine shaft near Wolfenbüttel, Germany). Since the past decades, ca. 220.000 m³ of weak radioactive waste have been deposited here; owing to geologic hazards, this waste may be relocated to the nearby “Schacht Konrad”.

EZN is one of the few private firms with a relevant expertise in tandem with a local infrastructure for the conditioning, i.e. shredding, compression, weighing, activity dosimetry and subsequent space-efficient charging of “Konrad” containers at the required quantity. Predominantly, this task is typically performed by government agencies (Landessammelstellen). Further, EZN enjoys a special permit for interstate transportation of radioactive waste within Germany. A special, proprietary deposit planning software allows for optimal container filling resulting in cost advantages and improved margins.

EZAG now plans to significantly increase the interim storage capacities at the Braunschweig location in order to accommodate for the waste recovered from “Asse” as well as their subsequent conditioning. The establishment of the essential infrastructure including a new depot requires ca. €20 Mill. of total investment, €10 Mill. of which shall originate from equity. This investment will position EZAG even stronger within this attractive market.

Owing in particular to the stringent regulatory and technical hurdles regarding permission-to-operate, the competitive arena is very limited. We identify the following companies which, based on their business operations, qualify for the routine conditioning of weak to mid radioactive waste and for the retrieval of waste from “Asse”.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

November 16, 2009

- **GNS (Gesellschaft für Nuklear-Service mbH)** is a highly profitable Joint Venture, operated by the larger energy combinations with locations in Germany, France, and the Czech Republic. Business activities – amongst others – are: waste service for nuclear power plants, maintenance, repair, and shutdown of nuclear facilities. The consolidated financial statement 2008 shows revenues of €242 Mill. and a result before taxes of €44 Mill. We would like to point out that to our knowledge the company's operations focus on the disposal of high-radioactive waste.
- **Energiewerke Nord GmbH;** sole shareholder is the Federal Ministry of Finance. The EWN-Group comprises companies dealing with the decommissioning of nuclear facilities. The radioactive residues/waste produced during the course of dismantling will be cut, treated, intermediately stored and delivered to the Federal Final Storage in the long term. The group represents the interests of the Federal Government, and the Federal States of Nordrhein-Westfalen and Baden-Württemberg. The group companies are institutional recipients of Federal and State appropriations and are being financed independently. In 2007, the group reported revenues of €23 Mill.
- **Gamma Service Recycling GmbH;** operations include: transport, storage, and recycling of radioactive waste. It is a smaller company with 46 employees in 2007
- **EnergySolutions, Inc.** is a US-based corporation with a current market capitalization of ca. \$800 Mio. The company perceives itself as a global market leader in the processing, recycling, and storage of radioactive waste. In 2008, revenues accounted for \$1.8 Bill. (previous year: \$1.1 Bill.). For 2009, the company forecasts a net result of up to \$53 Mill. It is conceivable that the company might wish to participate in the attractive market of radioactive waste retrieval and conditioning – maybe within the context of a partnership with one of the German companies.

A survey commissioned by the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz; „Beurteilung der Möglichkeit einer Rückholung der LAW-Abfälle aus der Schachanlage Asse“, September 2009; LAW = Low active waste) depicts four scenarios quantifying the total costs for waste retrieval in a range from €0.9 – 3.7 Bill. These costs are suggestive of the relevant economic potential on the part of the above mentioned service providers.

Regarding the retrieval and conditioning of weak radioactive waste deposited in Asse, EZAG's management perceives a top line potential of up to €250 Mill. within a period of six to eight years starting from 2011.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

2. Extension of the segment „Radiopharmazy“

In October '09, EZAG has signed a 10-year contract with the US-based drug development company Molecular Insight Pharmaceuticals (MIPI) for the production of a radio-therapeutical peptide (a Somatostatin analogon) designed for the treatment of neuroendocrine tumors. We anticipate this manufacturing contract to entail a signaling effect, which will attract further sponsors active in the development and production of radiotherapeuticals; EZAG as a leading player in radiopharmacy should be amongst their premier partners. In order to provide for sufficient contract manufacturing capacities, EZAG is budgeting investments of ca. €10 Mill. with an equity fraction of ca. €5 Mill.

3. Continuation of the consolidation strategy and expansion

Since inception, management identified and successfully realized numerous market opportunities in order to allow for a mid and long term growth in sales and earnings. EZAG strives to consistently pursue its Buy & Build strategy via acquisitions and geographic expansion. Strategic acquisitions within the segments “Therapy” and “N & I” will lead to a further consolidation in these niche markets, a process in which EZAG will continue to actively participate in the future.

In this context, the company intends the re-entry into the US market with its segment “Therapy” and the expansion of its operations to the Asian market. Based on our experience and knowledge of the company, management has consistently proven its ability to successfully execute acquisitions and to integrate the purchased companies with an emphasis on the improvement of profitability.

For short- and mid-term acquisitions as well as for the sake of strategic flexibility, EZAG anticipates capital requirements amounting to ca. €15 Mill. with an equity fraction of ca. €5 Mill.

In sum, the capital demand adds up to ca. €45 Mill., of which ca. €20 Mill. shall be raised in the context of the current corporate action (max. gross proceeds: €21.5 Mill.). In our model, we have accounted for loan proceeds in the years 2010, 2011, and 2012 (€10 Mill., €10 Mill., €5 Mill.).

We would like to mention, that “Eckert Wagniskapital und Frühphasenfinanzierung GmbH” will – within its budget – participate in the capital increase.

Eckert & Ziegler AG

November 16, 2009

Implications for Sales and Profits

Based on the anticipated organic growth, which we are still considering in our forecasts, we expect significant top and bottom line improvements, given the scheduled use of proceeds.

During the most recent analyst conference on Nov 11, 2009, management considers a doubling of sales up to €200 Mill. within reach by 2014 and guides for a stable net result of €1.80 per share for 2010 (based on the increased number of shares).

Regarding the upside potential in the context of the mine shaft "Asse", we presume a conservative scenario within our updated forecast, since we have to await the political discussion and their results (expected during 2011).

We have adjusted our DCF analysis which now returns an equity value of €88 Mill. or €16.72 per EZAG share. We also have updated our peer group and calculate a capital market-based value of €29.08 per share (based on P/E for 2010). Equally weighted, we calculate a fair share price of €22.90 (previous: €22.21).

Based on our DCF and peer group analysis as well as considering a current (2009) P/E ratio of 10.8, EZAG's stock is favorably valued. We recommend buying the stock and participating in the current capital increase.

Comments on Financials and the attached tables: For the EPS 2009, we calculate with an average of 3.756 Mill. shares outstanding; the balance sheet 2009 already includes the new shares. For the EPS calculation from 2010 onwards, we have adjusted the total number of shares with dividend rights to 5.26 Mill. The DCF- and multiple-derived values are both based on the total number of shares after capital increase, i.e. 5.26 Mill.

Details of the current capital increase

- Cash capital increase of up to 1.35 Mill. new shares at a strike price of €15.95
- Subscription period from Nov 19 - Dec 3, 2009 with a 14:5 ratio
- (the shareholder is entitled to receive five new shares for fourteen old shares)
- New shares are fully entitled to dividend for the business year 2009
- Purchase right for existing shareholders; the shareholders are offered an option to oversubscribe. Shares that have not been subscribed according to the legal subscription right are offered to interested investors at the subscription price within the framework of a private placement
- Trade of subscription rights excluded
- Effective date of listing is intended still in December, 2009

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Valuation Models

DCF Model

DCF analysis based on future free cash-flows 2009-2016 + Terminal Value

in T€ -	actual		Forecasting period								Terminal Value 2017+
	2008	2009e	Phase 1				Phase 2				
	Basis	1	2	3	4	5	6	7	8		
Growth		48%	11%	14%	20%	20%	4%	3%	3%	1%	
Revenues	71,612.0	105,827.0	117,100.0	133,720.0	160,406.0	191,822.2	199,495.1	205,480.0	211,644.4		
EBIT	9,469.0	14,179.0	19,270.3	20,005.3	30,615.8	32,609.8	33,914.2	34,931.6	35,979.5		
- Tax	3,292.0	4,962.7	6,744.6	7,001.8	10,715.5	11,413.4	11,870.0	12,226.1	12,592.8		
+ Depreciation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	11,509.3	11,969.7	12,328.8	12,698.7		
+ change in long-term provisions	8,054.0	0.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0		
- changes in net working capital	-1,584.0	292.4	96.3	142.0	228.1	547.4	76.7	59.8	61.6		
- other non-cash items	13,233.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
- Capex	5,461.0	10,000.0	14,320.0	13,197.6	15,332.5	17,845.8	18,459.6	16,438.4	16,931.6		
= Free Cash Flow	6,271.0	4,623.9	2,909.3	4,563.8	9,339.8	13,312.5	14,477.6	17,536.1	18,092.2	18,273.1	
Terminal Value	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	166,119.0	
Discount factor	0.0	0.89	0.80	0.71	0.64	0.57	0.51	0.45	0.40		
NPVs of Free Cash Flows	n.a.	4,128.5	2,319.3	3,248.4	5,935.6	7,553.9	7,334.8	7,932.4	7,307.1		
NPV of Terminal Value										67,092.7	

Valuation	Value	Proportion of EV
Result of Future Cash Flows	45,760.1	41%
+ Result of Terminal Value	67,092.7	59%
= Value of the Entity	112,852.8	
+ Cash	7,311.0	
- LT Debt	30,242.0	
- Minorities	1,964.0	
Value of Equity	87,957.8	
Price per Share	16.72	

Source: BankM Research

Peer Group Analysis

Company	Price	MarketCap (Mill.)	EPS			P/E		
			2008a	2009	2010	2008a	2009	2010
Europe								
aap Implantate AG	1.20	33.5	-0.20	0.05	0.07	neg.	24.00	17.14
Biolitec AG	4.10	43.11	0.19	0.06	0.16	21.58	68.33	25.63
Carl Zeiss Meditec AG	10.40	845.62	0.66	0.57	0.64	15.76	18.25	16.25
IBt	3.78	66.36	-0.16	0.23	0.32	neg.	16.43	11.81
Pulsion Medical Systems AG	2.80	26.82	-0.08	0.05	0.10	neg.	56.00	28.00
Stratec Biomedical Systems AG	23.89	273.37	0.54	0.98	1.27	44.24	24.38	18.81
UMS Medical Syst. Intl AG	6.37	34.49	0.54	0.61	0.64	11.80	10.44	9.95
W.O.M. World of Medicine AG	9.50	85.50	0.40	0.16	n.a.	23.75	59.38	n.a.
Wavelight AG	20.06	132.57	-0.27	0.12	0.78	neg.	167.17	25.72
Median		64.3	0.30	0.14	0.64	21.58	40.19	18.81
Eckert & Ziegler AG	19.33	75.08	1.43	1.79	1.80	13.49	10.83	10.76

Prices as of November 16, 2009

Year	2009	2010
Implicit Price	71.76	33.81
Discount 10%		29.08

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

November 16, 2009

Tables

P&L 9M and Quarterly Forecast 2009

Fiscal Year 31/12 • IFRS	2008a	9M/08a	9M/09a	Delta %	Q4/09e	2009e
Total Sales	71,612.0	51,454.0	77,827.0		28,000.0	105,827.0
Cost of Sales	37,453.0	29,305.0	37,454.0	27.8	13,720.0	51,174.0
<i>% of sales</i>	<i>52.3</i>	<i>57.0</i>	<i>48.1</i>		<i>49.0</i>	<i>48.4</i>
Gross Profit	34,159.0	22,149.0	40,373.0	82.3	14,280.0	54,653.0
Distribution Expenses	15,115.0	9,976.0	14,023.0	40.6	5,320.0	19,343.0
<i>% of sales</i>	<i>21.1</i>	<i>19.4</i>	<i>18.0</i>		<i>19.0</i>	<i>18.3</i>
Administrative Expenses	14,609.0	9,871.0	14,484.0	46.7	5,040.0	19,524.0
<i>% of sales</i>	<i>20.4</i>	<i>19.2</i>	<i>18.6</i>		<i>18.0</i>	<i>18.4</i>
R&D Expenses	3,108.0	3,409.0	1,725.0	-49.4	560.0	2,285.0
<i>% of sales</i>	<i>4.3</i>	<i>6.6</i>	<i>2.2</i>		<i>2.0</i>	<i>2.2</i>
Other Operating Income	17,241.0	2,631.0	878.0	-66.6	0.0	878.0
Other Operating Expenses	8,979.0	729.0	256.0	-64.9	0.0	256.0
Income from Ord. Business	9,589.0	795.0	10,763.0	<i>n.a.</i>	3,360.0	14,123.0
Foreign exchange gains/losses	51.0	154.0	49.0	-68.2	0.0	49.0
Other Financial Items	-171.0	13,988.0	7.0	*	0.0	7.0
Financial Result	-120.0	14,142.0	56.0	*	0.0	56.0
EBIT	9,469.0	14,937.0	10,819.0	-27.6	3,360.0	14,179.0
Interest Income	73.0	97.0	40.0	-58.8	0.0	40.0
Interest Expenses	1,241.0	702.0	1,068.0	52.1	387.0	1,455.0
EBT	8,301.0	14,332.0	9,791.0	-31.7	2,973.0	12,764.0
Taxes on Income	5,264.0	5,003.0	1,773.0	-64.6	1,040.6	2,813.6
Net Profit	3,037.0	9,329.0	8,018.0	-14.1	1,932.5	9,950.5
Result from discont'd Operations	-	-	97.0		-	97.0
Minorities	-1,465.0	-1,698.0	2,796.0	<i>n.a.</i>	545.2	3,341.2
Adjustments	0.0	0.0			0.0	0.0
Adjusted Net Profit	4,502.0	11,027.0	5,319.0	-51.8	1,387.2	6,706.2
<i>No. of Shares**</i>	<i>3,143</i>	<i>3,143</i>	<i>3,686</i>		<i>3,700</i>	<i>3,756</i>
Net Profit/Share (EPS)	1.43	3.51	1.44	-58.9	0.37	1.79

* due to special effects limited comparability, only; **for reported periods (a): Ø in circulation

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Profit & Loss Account

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e	CAGR
in T€						y-o-y changes (%)				
Total Sales	71,612.0	105,827.0	117,100.0	133,720.0	160,406.0	47.8	10.7	14.2	20.0	22.3
Cost of Sales	37,453.0	51,174.0	60,700.0	66,860.0	78,598.9	36.6	18.6	10.1	17.6	20.4
Gross Profit	34,159.0	54,653.0	56,400.0	66,860.0	81,807.1	60.0	3.2	18.5	22.4	24.4
Distribution Expenses	15,115.0	19,343.0	20,160.0	22,732.4	25,665.0	28.0	4.2	12.8	12.9	14.2
General & Admin. Expenses	14,609.0	19,524.0	20,109.7	20,110.8	20,714.1	33.6	3.0	0.0	3.0	9.1
R&D Expenses	3,108.0	2,285.0	3,360.0	4,011.6	4,812.2	-26.5	47.0	19.4	20.0	11.5
Other Operating Income	17,241.0	878.0	6,500.0	0.0	0.0					
Other Operating Expenses	8,979.0	256.0	0.0	0.0	0.0					
Income from Ord. Business	9,589.0	14,123.0	19,270.3	20,005.3	30,615.8	47.3	36.4	3.8	53.0	33.7
Foreign exchange gains/losses	51.0	49.0	0.0	0.0	0.0					
Other Financial Items	-171.0	7.0	0.0	0.0	0.0					
Financial Result	-120.0	56.0	0.0	0.0	0.0					
EBIT	9,469.0	14,179.0	19,270.3	20,005.3	30,615.8	49.7	35.9	3.8	53.0	34.1
Interest Income	73.0	40.0	50.0	50.0	50.0					
Interest Expenses	1,241.0	1,455.0	1,700.0	1,400.0	1,100.0					
EBT	8,301.0	12,764.0	17,620.3	18,655.3	29,565.8	53.8	38.0	5.9	58.5	37.4
Taxes on Income	5,264.0	2,813.6	6,167.1	6,529.3	10,348.0					
Net Profit	3,037.0	9,950.5	11,453.2	12,125.9	19,217.8	227.6	15.1	5.9	58.5	58.6
Result from discontinued Operations	-	97.0	-	-	-					
Minorities	-1,465.0	3,341.2	2,000.0	2,000.0	2,000.0					
Adjustments	0.0	0.0	0.0	0.0	0.0					
Adjusted Net Profit	4,502.0	6,706.2	9,453.2	10,125.9	17,217.8	49.0	41.0	7.1	70.0	39.8
<i>For Information purposes</i>										
Depreciation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	-37.7	1.8	1.7	1.7	-10.0
EBITDA	18,619.0	19,879.0	25,070.3	25,905.3	36,615.8	6.8	26.1	3.3	41.3	18.4
No. of Shares (Ø outstanding)	3,143	3,756	5,260	5,260	5,260	19.5	40.0	0.0	0.0	13.7
Net Profit/Share (EPS)	1.43	1.79	1.80	1.93	3.27	24.6	0.7	7.1	70.0	23.0

Source: BankM Research

Cash Flow Statement

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e	CAGR
in T€						y-o-y changes (%)				
Net Profit	3,037.0	9,950.5	11,453.2	12,125.9	19,217.8	227.6	15.1	5.9	58.5	58.6
+ Depreciation & Amortisation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	-37.7	1.8	1.7	1.7	-10.0
+ Chg. in long-term Provisions	8,054.0	0.0	-1,000.0	-1,000.0	-1,000.0	n.a.	0.0	0.0	0.0	n.a.
= Cash Earnings	20,241.0	15,650.5	16,253.2	17,025.9	24,217.8	-22.7	3.9	4.8	42.2	4.6
- other non-cash items	13,233.0	0.0	0.0	0.0	0.0					
- Chg. in Net Working Capital	-1,584.0	292.4	96.3	142.0	228.1	n.a.	-67.1	47.4	60.6	-8.0
= Operating Cash Flow	8,592.0	15,358.0	16,156.8	16,883.9	23,989.7	78.7	5.2	4.5	42.1	29.3
- Capex	5,461.0	10,000.0	14,320.0	13,197.6	15,332.5	83.1	43.2	-7.8	16.2	29.4
= Free Cash Flow	3,131.0	5,358.0	1,836.8	3,686.3	8,657.3	n.a.	n.a.	100.7	134.9	29.0
+ Net Other Items	59.0	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	0.0	n.a.
- Dividends (Previous Year)	786.0	1,110.0	1,676.6	2,363.3	2,531.5	41.2	51.0	41.0	7.1	34.0
- Payout minorities	103.0	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	0.0	n.a.
+ Increase in Share Capital	0.0	24,673.2	0.0	0.0	0.0					
- Outflow from Share Buy Backs	0.0	0.0	0.0	0.0	0.0					
+/- Bank Loans	635.0	2,500.0	10,000.0	10,000.0	5,000.0					
= Incr. in Cash (+)/Decr. in Cash (-)	2,936.0	31,421.2	10,160.3	11,323.0	11,125.8	970.2	-67.7	11.4	-1.7	39.5

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

November 16, 2009

Balance Sheet

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e
in T€									
Assets						% of Balance Sheet Total			
Tangible Assets	23,807.0	28,107.0	36,627.0	43,924.6	53,257.1	18%	20%	21%	22%
Other Assets	41,332.0	48,224.0	50,494.8	53,842.6	59,218.0	31%	28%	26%	24%
<i>t/o Goodwill</i>	26,907.0	26,907.0	26,907.0	26,907.0	26,907.0	17%	15%	13%	11%
Total Fixed Assets	65,139.0	76,331.0	87,121.8	97,767.2	112,475.1	50%	49%	47%	46%
Inventories	8,555.0	12,642.4	13,989.1	15,974.6	19,162.6	8%	8%	8%	8%
Accounts Receivable	13,985.0	20,666.8	22,868.3	26,114.0	31,325.4	13%	13%	13%	13%
Total Liquid Funds	7,311.0	38,732.2	48,892.5	60,215.5	71,341.3	25%	27%	29%	29%
Other Current Assets	3,808.0	5,627.4	6,226.8	7,110.6	8,529.7	4%	3%	3%	4%
Total Current Assets	33,659.0	77,668.8	91,976.8	109,414.7	130,359.0	50%	51%	53%	54%
Balance Sheet Total	98,798.0	153,999.9	179,098.5	207,181.9	242,834.1	100%	100%	100%	100%
Liabilities						% of Balance Sheet Total			
Subscribed Capital	3,250.0	5,260.0	5,260.0	5,260.0	5,260.0	3%	3%	3%	2%
Share Premium	30,316.0	54,989.2	54,989.2	54,989.2	54,989.2	36%	31%	27%	23%
Retained Earnings & Other Reserves	7,290.0	12,886.2	20,662.8	28,425.5	43,111.8	8%	12%	14%	18%
Shareholders Equity	40,856.0	73,135.4	80,912.0	88,674.6	103,360.9	47%	45%	43%	43%
Minorities	1,964.0	5,202.2	7,202.2	9,202.2	11,202.2	3%	4%	4%	5%
Group Equity	42,820.0	78,337.6	88,114.2	97,876.9	114,563.2	51%	49%	47%	47%
Provisions	16,389.0	16,389.0	15,389.0	14,389.0	13,389.0	11%	9%	7%	6%
<i>t/o Pension Provisions</i>	420.0	620.7	686.8	784.3	940.8	0%	0%	0%	0%
Other Liabilities	39,589.0	59,273.3	75,595.3	94,916.0	114,881.9	38%	42%	46%	47%
Total Liabilities	55,978.0	75,662.3	90,984.3	109,305.0	128,270.9	49%	51%	53%	53%
<i>t/o LT Liabilities</i>	30,242.0	37,630.1	48,900.7	61,248.6	70,624.0	24%	27%	30%	29%
<i>t/o ST Liab. <1Y</i>	25,736.0	38,032.2	42,083.5	48,056.4	57,646.9	25%	23%	23%	24%
Balance Sheet Total	98,798.0	153,999.9	179,098.5	207,181.9	242,834.1	100%	100%	100%	100%

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Important information, disclosures and disclaimer

A. Important information

Equity investments generally involve high risks. Investors may lose some or all of the money invested. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Past performance is no guarantee for future results. Investors make their decisions at their own risk.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV):

I. Information about author, company held accountable, regulatory authority:

Responsible for the content of this document: biw Bank für Investments und Wertpapiere AG, Willich, Germany.

Author: Dr. Roger Becker, CEFA, Biologist

Regulatory authority for biw Bank für Investments und Wertpapiere AG is the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Issuer of the analyzed instrument is Eckert & Ziegler AG.

Notice according to sec. 4 §. 4 N^o 4 FinAnV (previous publications regarding the issuer within the last 12 months):

Analyst	Date	Evaluation result	Fair Value
Dr. Roger Becker	April 1, 2009	Buy	€10.56
Dr. Roger Becker	May 5, 2009	Buy	€10.56
Dr. Roger Becker	July 10, 2009	Buy	€14.50
Dr. Roger Becker	August 7, 2009	Neutral	€19.26
Dr. Roger Becker	November 4, 2009	Buy	€22,21

II. Additional Information:

1. Sources of information:

Main sources of information for the compilation of this document are publications in national and international media and information services (e.g. Reuters, VWD, Bloomberg, dpa-AFX and others), financial newspapers and magazines (e.g. Börsenzeitung, Handelsblatt, Frankfurter Allgemeine Zeitung, Financial Times and others), specialist media, published statistics, rating agencies as well as publications by peer group companies and the company itself. Furthermore talks with the management of the issuer have been held. This document was made available to the issuer before publication to ensure the accuracy of the information provided. This did not result in any changes.

2. Summary of the valuation principles and methods used to prepare this document:

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG uses a 3-tier absolute rating model. The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up to 12 months.

BUY: The calculated fair value of the company's stock is at least 15 % higher than the current market price at the time of the compilation of this document.

NEUTRAL: The calculated fair value of the company's stock lies between –15% and +15 % of the current market price at the time of the compilation of this document.

SELL: The calculated fair value of the company's stock is at least 15 % lower than the current market price at the time of the compilation of this document.

The following valuation methods are being used: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITA, EV/EBITDA), peer-group comparisons, historical valuation approaches, discount models (DCF, DDM), break-up value and sum-of-the-parts-approaches, asset-based evaluation methods or a combination of the above. The used valuation models depend on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Additionally, market sentiment affects the valuation of companies. The valuation is also based on expectations that might change rapidly and without notice, depending on developments specific to individual industries. Rendered evaluation results and fair values derived from the models might therefore change respectively. The evaluation results in general relate to a 12-month horizon. However, evaluation results are subject to changing market conditions and represent only the situation at a given point of time. The evaluation results and fair value prices may in fact be achieved more quickly or slowly than expected by the analysts. Also, the evaluation results and fair value prices might need to be revised upward or downward.

3. Date of first publication of this document:

November 16, 2009

4. Date and time of prices of the instruments quoted in this document:

Closing prices of November 16, 2009

5. Updates:

A specific date or time for an update of this document has not been set. The information given in this document reflects the author's judgement on the date of this publication and is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the company covered. It is in the sole responsibility of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to decide on a potential update of this document.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

November 16, 2009

III. Disclosures about potential conflicts of interest:

1. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's business model is based on economic relationships with issuers and equity transactions to be performed relating to the issuer's stock. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG has entered into an agreement about the preparation of this document with the issuer that is, or whose financial instruments are, the subject of this document.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG was mandated as lead bank for the rights issue of Eckert & Ziegler AG conducted in January/February 2009 and, in this connection, has been party to an agreement on the provision of investment banking services with the issuer that is, or whose financial instruments are, the subject of this document. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is also lead bank and bookrunner in the current share issue.

Moreover, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is party to an other agreement on the provision of investment banking services with the issuer that is, or whose financial instruments are, the subject of this document.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG (incl. subsidiaries and affiliates), the authors of this document as well as other persons that were involved in the compilation of this document or affiliated parties:

- **do not have a major shareholding (shareholding exceeding 5%) of the share capital of the issuer that is, or whose financial instruments are, the subject of the analysis. Board members, directors, employees or clients of biw Bank für Investments und Wertpapiere AG possibly are holders of instruments that are mentioned in this document (or that are related to these instruments) or could become holders and could regularly trade the issuer's securities or securities based on these issues as principal or agent,**
- **have no other significant economic interests relating to the issuer that is, or whose financial instruments are, the subject of this analysis.**

2. In the function as a designated sponsor, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG manages the financial instruments that are, or whose issuers are, the subject of the financial analysis on a market by placing buy or sell orders and will regularly hold a trading stock or long or short positions in the issuer's stock.

3. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's internal organisation is aligned with the prevention of conflict of interests in producing and distributing research reports. Possible conflicts of interests will be treated adequately. In particular, physical and non-physical boundaries were installed to keep analysts from gaining access to information that possibly could constitute a conflict of interest for the bank. biw Bank für Investments und Wertpapiere AG keeps insider registers according to sec. 15 WpHG for employees and assignees that normally have access to inside information. These registers will be transmitted to BaFin on request. Insiders' dealings according to sec. 14 WpHG categorically are prohibited. Staff members that fill a specific position and have access to inside information categorically have to disclose all dealings in financial instruments to the internal compliance department. The compliance of legal requirements and supervisory regulations is subject to continuous supervision and control of the compliance department of biw Bank für Investments und Wertpapiere AG. In this regard, the right to restrict employees' dealings in financial instruments is reserved.

4. The remuneration of the analysts mentioned above is not dependent on any investment banking transactions of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG or its affiliates. The analysts that compiled this document did not receive or acquire shares in the issuer that is, or whose financial instruments are, the subject of this document at any time. The analysts mentioned above hereby certify that all of the views expressed accurately reflect his or her personal views about the issuer and that no part of his or her compensation was, is or will be, directly or indirectly, related to the specific evaluation result or views expressed by the analyst in this document.

5. Updated information according to sec. 5 para. 4 N^o. 3 FinAnV is available at: http://www.bankm.de/webdyn/138_cs_Gesetzliche+Angaben.html.

C. Disclaimer:

This document was compiled by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG solely for informational purposes and for the personal use by persons in Germany that are interested in the company and who purchase or sell transferable securities for their own account or the account of others in the context of their trade, profession or occupation. This document neither constitutes a contract nor any kind of obligation.

This document and its content, in whole or in part, may not be reproduced, distributed, published or passed on to any other person without the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG.

This publication is for distribution in or from the United Kingdom only with the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made there under or to investment professionals as defined in Section 19(5) of the Financial Services and Markets Act 2000 (financial promotion) order 2005 (the order) respectively in the version as amended from time to time and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof.

The distribution of this document in other jurisdictions may be restricted by law, and persons who are in possession of this document have to inform themselves about any such restrictions and observe any such restrictions.

This document is not intended to be an offer, or the solicitation of any offer, or any advice or recommendation to buy or sell the securities referred to herein. This document is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Potential investors should seek professional and individual advice before making their investment decisions. Investment decisions must not be based on this document.

The information within this document has been obtained from sources believed by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to be reliable, but BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Although due care has been taken in compiling this document, it cannot be excluded that the information given is incomplete or the document contains errors. The liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG shall be restricted to gross negligence and wilful misconduct. All opinions expressed in this document are those of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG respectively the authors and subject to change without notice. Possible errors or incompleteness of this document may be corrected by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and do not constitute grounds for liability, neither with regard to indirect nor to direct or consequential damages. Only in case of failure in essential tasks, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is liable for simple negligence. In addition BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not accept any liability or responsibility for any loss arising from any use of this publication or its contents or otherwise arising in connection herewith. In any case, the liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is limited to typical, foreseeable damages and the liability for any indirect damages is excluded.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

By accepting this document, the reader/user of this document agrees to be bound by all of the foregoing provisions and this disclaimer. Moreover, the user agrees not to distribute this document to unauthorized persons. The user of this document shall indemnify BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG for any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

Should certain specifications of this disclaimer not be legally binding or become legally non-binding, this will have no impact on the legally binding character of this disclaimer and its other legal specifications.

This document is not intended for use by persons resident in any jurisdiction that regulates access to such documents by applicable laws. Investment decisions must not be based on any statement in this document. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. In case of uncertainty persons should not access and/or consider the content of this document in any decisions. This document is not intended for use by persons that are classified as US-persons under the United States Securities Act.

© 2009 BankM - Repräsentanz der biw Bank für Investments und Wertpapiere AG, Mainzer Landstraße 61, D-60329 Frankfurt.

biw Bank für Investments und Wertpapiere AG, Hausbroicher-Straße 222, D-47877 Willich. All rights reserved.

This document is a translation of the legally binding German original version of November 16, 2009.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!